the most studied member of the type I receptor tyrosine kinase family, is present in up to 25% of women with breast cancer and is associated with a poor prognosis. EGFR (ErbB1), another member of ...

The molecular basis of phospho-tyrosyl-regulation of Src-family and Syk-family protein tyrosine kinases in signaling ... We are also actively investigating the regulation of Syk tyrosine kinase ...

Since the discovery and first therapeutic administration of insulin as an injectable medication in 1922, development of an orally administered insulin, or insulin-mimetic has been the 'holy grail ...

Aberrant activation of the Src family of tyrosine kinases has been implicated ... of combination therapy with epidermal growth factor receptor inhibition and cytotoxic chemotherapy.

Dr. Gao Guo is an assistant professor in the UAB Department of Neurosurgery. His research focuses on elucidating the role of receptor tyrosine kinase in the invasion and survival of glioblastoma (GBM) ...

Researchers at Children's Hospital of Philadelphia (CHOP) and the Children's Oncology Group (COG) found that larotrectinib, ...

with broad market prospects. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Rare NRG1 Fusion Therapeutics ...

NEU-111 is a potent and highly selective oral allosteric inhibitor of tyrosine kinase 2 (TYK2), a JAK family protein that ... through several cytokine receptors, including receptors for ...

a tropomyosin receptor kinase (TRK) inhibitor. It targets cells with constitutive activation of TRK proteins resulting from gene fusions and the proto-oncogene tyrosine-protein kinase ROS (ROS1).